Ireland-based medical device company Medtronic has introduced its MiniMed 630G system with SmartGuard technology in the US to treat people with diabetes.

The MiniMed 630G is fitted with a new insulin pump hardware platform and a new user-friendly design which assists in personalised diabetes management.

The waterproof pump design introduces bolus functionality and features a high-definition, full-colour screen which aids an easy navigation while enabling increased customisation with menus.

The MiniMed 630G system uses the CONTOUR NEXT LINK 2.4 blood glucose meter from Ascensia Diabetes Care which offers blood glucose test results with accuracy.

The results are automatically relayed to calculate boluses using the Bolus Wizard calculator and to calibrate the CGM sensor prevents chances of manual entry errors.

The system also enables the patients to administer bolus of insulin remotely from the meter thereby allowing the patients to manage their diabetes effectively.

"The system also enables the patients to administer bolus of insulin remotely from the meter thereby allowing the patients to manage their diabetes effectively."

Medtronic intensive insulin management business president Alejandro Galindo said: "This latest innovation demonstrates Medtronic's vision to transform diabetes care to enable greater freedom and better health through a commitment to continually improving both outcomes and user experience."

The MiniMed 630G system is based on its patented SmartGuard technology which also featured in the MiniMed 530G system.

The new pump platform integrates continuous glucose monitoring (CGM) and SmartGuard technology which sets off an alarm when the CGM sensor glucose level reaches a preset low threshold and holds off the delivery of insulin if the alarm is not addressed with an immediate response.


Image: MiniMed 630G System. Photo: courtesy of Medtronic plc.